ExLibris header image
SFX Logo
Title: miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Source:

Nature Communications [2041-1723] yr:2016


Collapse list of basic services Basic
Full text
Full text available via Nature
GO
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Ochiya, T. "The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer." Molecular therapy 23.4 (2015): 717-727. Link to Full Text for this item Link to SFX for this item
2. Wang, Huizhong i. "Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia." Cellular signalling 27.3 (2015): 443-52. Link to SFX for this item
3. Watanabe, R. "Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity." Journal of Clinical Investigation 127.7 (2017): 2725-2738. Link to Full Text for this item Link to SFX for this item
4. Abiko, K. "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer." British Journal of Cancer 112.9 (2015): 1501-9. Link to Full Text for this item Link to SFX for this item
5. Liu, Patrick i. "The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4." Clinical cancer research 21.7 (2015): 1639-51. Link to SFX for this item
6. Qin, S. "Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression." Nature communications 5.1 (2014): 5241-5241. Link to Full Text for this item Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.